Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
2.

Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.

Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, Finckenstein FG, Park JS, Roy A.

Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842.

3.

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.

Wang X, Feng Y, Bajaj G, Gupta M, Agrawal S, Yang A, Park JS, Lestini B, Roy A.

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):40-48. doi: 10.1002/psp4.12133. Epub 2016 Dec 26.

4.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B.

J Immunother Cancer. 2016 Nov 15;4:72. eCollection 2016.

5.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.

Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.

PMID:
26310975
6.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR.

N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.

7.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

8.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

9.

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.

Cancer Res. 2012 Feb 15;72(4):969-78. doi: 10.1158/0008-5472.CAN-11-1875. Epub 2011 Dec 28.

10.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.

Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.

11.

An unusual case of gastrointestinal bleeding.

Fiorino KN, Lestini B, Nichols KE, Anupindi SA, Maqbool A.

Case Rep Pediatr. 2011;2011:748543. doi: 10.1155/2011/748543. Epub 2012 Jan 22.

12.

BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.

Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X, Hogarty MD.

Cell Death Differ. 2010 May;17(5):872-82. doi: 10.1038/cdd.2009.171. Epub 2009 Nov 6.

13.

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD.

Cancer Biol Ther. 2009 Aug;8(16):1587-95. Epub 2009 Aug 8.

14.

Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas.

Kreiger PA, Judkins AR, Russo PA, Biegel JA, Lestini BJ, Assanasen C, Pawel BR.

Mod Pathol. 2009 Jan;22(1):142-50. doi: 10.1038/modpathol.2008.185. Epub 2008 Nov 7.

16.

RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.

Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE.

Thromb Haemost. 2005 Jan;93(1):106-14.

PMID:
15630499
17.

Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery.

Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, Case AJ, Kottke-Marchant K, Anderson JM, Marchant RE.

J Control Release. 2002 Jan 17;78(1-3):235-47.

PMID:
11772464
18.

Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.

Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE.

Blood. 1996 Oct 15;88(8):2939-50.

PMID:
8874190
19.

Surface analysis of clinically used expanded PTFE endoscopic tubing treated by the STERIS PROCESS.

Tucker RC, Lestini BJ, Marchant RE.

ASAIO J. 1996 Jul-Aug;42(4):306-13.

PMID:
8828789

Supplemental Content

Loading ...
Support Center